Results of a phase III clinical trial of the drug Enzalutamide, published recently in the New England Journal of Medicine, show the drug extends life by an average five months in the most advanced stages of prostate cancer. "This is a major advance. Not only do we see more survival benefit than from traditional chemotherapy, but the side effects of Enzalutamide are much lower...
More...
More...